The macula, being responsible from central, color and sharp vision can be named as the eye of the eye. The disease of macula is called age related macular degeneration (AMD).
AMD is the major cause of decreased vision with ageing and can be seen under various circumstances in young people. Both of the eyes are affected and its peak incidence is seen in people over 60 years of age. AMD has different phases and eventually macular cells are damaged from the disease. This can result in sudden or gradually decrease in vision. Data of World Health Organisation (WHO) show that nearly 30 million people have AMD and 8.7% of them haveseverely decreased vision.
In the beginning of the disease trouble in reading occurs and objects get blurry. This symptoms show that the person have a dry type AMD. Ten percent of patients precede into the wet type of AMD. The transition reveals itself by increase in deterioration of vision and seeing the lines wavy at Amsler grid or doors.
Your ophthalmologist will decide for a treatment following the examination and tests.
AMD treatment can be performed only to a limited group of the disease. The aim of treatment is to stop the advancement of AMD and saving vision.
Ranibizumab (Lucentis) and bevacizumab (Avstin) are the 2 drugs used for treatment, they are injected intravitreally by a period of 4-6 weeks and repeated 3 times initially. Photodynamic therapy (PDT) is also a treatment option.
The patient will be followed up if he/she is not a candidate for treatment. In this case an Amsler grid test are recommended for the patient to follow himself/herself up. Multivitamin capsules made for the retinal micronutrition in AMD are also recommended.